Overview

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors

Status:
Recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

This is an open-label, First-in-Human, dose escalation and dose expansion study of THOR-707 (Monotherapy and Combination Therapy) in adult subjects with advanced or metastatic solid tumors.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Synthorx, Inc, a Sanofi company
Synthorx, Inc.

Treatments:

Antibodies
Interleukin-2